Cargando…
Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease
Convalescent plasma (CP) therapy in COVID-19 disease may improve clinical outcome in severe disease. This pilot study was undertaken to inform feasibility and safety of further definitive studies. This was a prospective, interventional and randomized open label pilot trial in patients with severe CO...
Autores principales: | AlQahtani, Manaf, Abdulrahman, Abdulkarim, Almadani, Abdulrahman, Alali, Salman Yousif, Al Zamrooni, Alaa Mahmood, Hejab, Amal Hamza, Conroy, Ronán M., Wasif, Pearl, Otoom, Sameer, Atkin, Stephen L., Abduljalil, Manal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113529/ https://www.ncbi.nlm.nih.gov/pubmed/33976287 http://dx.doi.org/10.1038/s41598-021-89444-5 |
Ejemplares similares
-
Time Till Viral Clearance of Severe Acute Respiratory Syndrome Coronavirus 2 Is Similar for Asymptomatic and Non-critically Symptomatic Individuals
por: Kumar, Nitya, et al.
Publicado: (2021) -
COVID-19 and sickle cell disease in Bahrain
por: AbdulRahman, Abdulkarim, et al.
Publicado: (2020) -
The prevalence of asymptomatic and symptomatic COVID-19 in a cohort of quarantined subjects
por: Al-Qahtani, Manaf, et al.
Publicado: (2021) -
Is sickle cell disease a risk factor for severe COVID‐19 outcomes in hospitalized patients? A multicenter national retrospective cohort study
por: Abdulrahman, Abdulkarim, et al.
Publicado: (2021) -
Quarantining arriving travelers in the era of COVID-19: balancing the risk and benefits a learning experience from Bahrain
por: Abdulrahman, Abdulkarim, et al.
Publicado: (2021)